- Accesswire•4 days ago
NEW YORK, NY / ACCESSWIRE / October 20, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it ...
- PR Newswire•19 days agoTapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016
TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its President and Chief Operating Officer, Dr. John Bonfiglio, will be a speaker and deliver a corporate presentation at the BioNetwork Partnering Summit on Wednesday, October 5 at 4:35 PM PT. Dr. Bonfiglio will speak on the first day of the event focused on "The Latest Trends in Biopharma Partnering." TapImmune collaborations with organizations including the Mayo Clinic and the U.S. Department of Defence, Memorial Sloan Kettering and AstraZeneca will be discussed. Conference attendees seeking a one-on-one meeting with Dr. Bonfiglio may contact TapImmune directly, or contact BioNetwork West.
- PR Newswire•20 days agoTapImmune Recognizes National Breast Cancer Awareness Month With Renewed Urgency to Develop Cancer Vaccines
TapImmune, Inc., (TPIV, TPIVD), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is celebrating the month of October by reinforcing its efforts to prevent and cure breast and ovarian cancer. In an open letter posted on the TapImmune website, the company's Chairman and CEO, Glynn Wilson, Ph. D, paid tribute to friends and loved one's who have been affected by cancer during National Breast Cancer Awareness Month. Breast cancer is the most common cancer among women in the United States.
TapImmune, Inc. (TPIV)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||4.50 - 4.60|
|52wk Range||0.40 - 6.25|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||1.02|
|Avg Vol (3m)||184,871|
|Dividend & Yield||N/A (N/A)|